Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 3/20 | 0.64 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | MAPK10 | P53779 | 14/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6484542 | 0.86 | MAPK8 (0.62) | MAPK8MAPK9EGFRMAPK10 | |
| SCHEMBL6479091 | 0.85 | EGFR (0.62) | MAPK8MAPK9EGFRMAPK10 | |
| SCHEMBL6487771 | 0.84 | MAPK8 (0.66) | MAPK8MAPK9EGFRMAPK10CDK4 | |
| SCHEMBL6476578 | 0.83 | MAPK8 (0.71) | MAPK8MAPK9EGFRMAPK10CCNE1 | |
| SCHEMBL6489073 | 0.83 | MAPK8 (0.71) | MAPK8MAPK9EGFRMAPK10CCNE1 | |
| SCHEMBL6483479 | 0.80 | MAPK8 (0.68) | MAPK8MAPK9EGFRMAPK10CCNE1 | |
| SCHEMBL6477504 | 0.80 | MAPK8 (0.68) | MAPK8MAPK9EGFRMAPK10CCNE1 | |
| SCHEMBL6477463 | 0.79 | MAPK9 (0.77) | MAPK8MAPK9EGFRMAPK10CDK4 | |
| SCHEMBL6477585 | 0.79 | MAPK8 (0.64) | MAPK8MAPK9EGFRMAPK10CDK4 | |
| SCHEMBL6485328 | 0.78 | EGFR (1.00) | MAPK8MAPK9EGFRMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6891039-B2 | Imidazo [4,5-B] pyridine compounds and their pharmaceuticals use | NOVARTIS AG (CH) | 2005-05-10 | — | — | US | claimed |
| US-20040082604-A1 | Thiazole and imidazo (4,5-B) pyridine compounds and their pharmaceutical use | REVESZ LASZLO (CH) | 2004-04-29 | — | — | US | claimed |
| US-6891039-B2 | Imidazo [4,5-B] pyridine compounds and their pharmaceuticals use | NOVARTIS AG (CH) | 2005-05-10 | — | — | US | disclosed |
| US-20040082604-A1 | Thiazole and imidazo (4,5-B) pyridine compounds and their pharmaceutical use | REVESZ LASZLO (CH) | 2004-04-29 | — | — | US | disclosed |
| US-6608072-B1 | Inhibiting production of soluble tumor necrosis factor or reducing inflammation | NOVARTIS AG (CH) | 2003-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082604-A1 | Thiazole and imidazo (4,5-B) pyridine compounds and their pharmaceutical use | MAPK1, IRAK1, IRAK4 | MAPK8 42/4885MAPK9 43/4885EGFR 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.